Generative AI Remains at an IP and Privacy Crossroads

Content Factory Banner Ad

 

As artificial intelligence becomes increasingly integrated into our daily lives and business operations, the conversation around its ethical and legal implications grows louder. It’s clear that generative AI will continue to face legal battles; applications from oncology, to mental health services, to the classroom, are raising questions about AI’s ethics and the consequences of not addressing concerns before they cause undue harm. Two of the more persistent battlegrounds that are leading the legal debate around generative AI are intellectual property, as well as the world of data privacy.

For example, a recent congressional hearing from the Judiciary Committee Subcommittee on Intellectual Property emphasized the urgent need for clearer guidelines on IP protection for AI-generated works, highlighting the risk of stifling U.S. competitiveness under current policies and AI’s profound impact on intellectual property rights, recognizing its significant role in creativity and invention.

In the world of data privacy, despite strong interest in the productivity benefits of generative AI, U.S. leaders face major challenges in deploying AI tools safely, including a lack of strategic planning, governance, and in-house skills. New research from Coleman Parkes Research and SAS found that only 10% of organizations feel prepared for regulatory compliance, with most lacking a comprehensive governance framework.

The rise of generative AI, particularly in contexts that blend creativity and commerce, presents a complex challenge for intellectual property law, and privacy concerns still loom large as AI systems incorporate personal data into their vast training sets. Where does this leave the legal debate around generative AI? Jon Stine, an AI ethicist and seasoned retail technology executive, former leader at the Open Voice Network, weighs in with his analysis.

“In this observer’s opinion, it’s wise and ethical to use a large language model that at the very least places an emphasis
and respects sourcing and citation,” Stine said.

Article written by Daniel Litwin.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More